港股异动 | 四环医药(00460)逆市涨近4% 旗下减重药临床试验申请获受理 减肥药板块利好频出
四环医药(00460)逆市涨近4%，截至发稿，涨1.85%，报0.55港元，成交额400.32万港元。
消息面上，四环医药近日公布，集团旗下非全资附属公司惠升生物研发的司美格鲁肽注射液用于超重或肥胖的临床试验申请(IND申请)已获中国国家药监局受理。据悉，2023年司美格鲁肽全球总销售额已超两百亿美元，其中，司美格鲁肽注射液减重销售额约四十五亿美元，同比增长超400%。
值得注意的是，减肥药板块近期利好频出。诺泰生物预计2024年上半年归母净利润可达1.8亿元至2.5亿元，与上年同期相比增加330.08%至497.34%。据悉，司美格鲁肽系列产品是诺泰生物主要贡献收入的原料药品种。此外，丹麦明星减肥药厂Zealand发布成绩单 新药实现16周减重8.6%。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.